Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 2

Conditions

Anemia 7Neoplasms 3Multiple Myeloma 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Neoplasm Metastasis 1Mycosis Fungoides 1Motor Activity 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Neoplasms × Epoetin Alfa × Clear all
NCT00267007 2014-06-04

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
32 enrolled 9 charts

Neoplasms, Peripheral Nervous System Diseases

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
235 enrolled 13 charts
Classical hematology

Anemia, Neoplasms

NCT01394991 2012-04-05

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 4 Completed
504 enrolled 17 charts
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡